India's Dr Lal PathLabs rises as Axis Securities initiates with 'buy'
BUZZ-India's Dr Lal PathLabs rises as Axis Securities initiates with 'buy' ** Shares of India's Dr. Lal Path Labs DLPA.NS rise 2.91% to 1,989.90 rupees
** Axis Securities initiates coverage with "buy" rating and target price of 2,315 rupees, implying ~20% upside from last close
** Brokerage expects co's expansion into smaller cities and growing demand for preventive healthcare tests to drive revenue growth
** Says company's preventive wellness business has grown at about 25% annually, with its contribution to revenue rising to 27% in FY26 from about 15% in FY20
** Forecasts revenue growth of 15% in FY27 and 14% in FY28, supported by higher testing volumes and revenue per patient
** DLPA rated "buy" on average by 25 analysts, median PT at 2,030 rupees--LSEG compiled data
** YTD stock up 34.22%
(Reporting by Surbhi Misra in Bengaluru)
((Surbhi.Misra@thomsonreuters.com | X: https://twitter.com/SurbhiMisra_ |;))
Recent news on Dr. Lal PathLabs
See all newsBrief: Lal Pathlabs Says Unit Acquired Remaining 30% Equity Stake In Centrapath Labs Private Limited
India's Dr Lal PathLabs rises as Axis Securities initiates with 'buy'
India's Dr Lal PathLabs rises; analysts back SN Genelab deal
Brief: Lal Pathlabs Says Subsidiary Incorporated Dr Lal Pathlabs Indomed In Tashkent, Uzbekistan
India's Dr Lal PathLabs jumps to 4-year high after quarterly profit rise